Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3034 - Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL STUDY


29 Sep 2019


Poster Display session 2


Tumour Site

Breast Cancer


Maria Agnese Fabbri


Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240


M.A. Fabbri1, A. Botticelli2, C. Omarini3, E. Cretella4, A. Fabi5, D. Alesini6, L. Pizzuti5, G. piesco7, A. vaccaro8, F. Atzori9, F. Piacentini3, L. Moscetti10, A. Orlandi11, V. sini12, A. Mercanti13, M.L. framarino7, M. PERSANO14, R. Ceccherini15, E.M. Ruggeri16

Author affiliations

  • 1 Oncology Department, Belcolle Hospital, 01100 - viterbo/IT
  • 2 Clinical And Molecular Medicine Dept., Azienda Ospedaliera St. Andrea, 00189 - Rome/IT
  • 3 Oncology Department, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 4 Oncology Department, Ospedale Centrale di Bolzano ASDAA/SABES, 39100 - Bolzano/IT
  • 5 Oncology Department, Istituto Nazionale Tumori Regina Elena, 00144 - Rome/IT
  • 6 Medical Oncology, Central Hospital of Belcolle, 01100 - Viterbo/IT
  • 7 Oncology Department, policlinico Umberto I, 00149 - rome/IT
  • 8 Oncology Department, Frosinone, 00000123 - frosinone/IT
  • 9 Oncology Department, Azienda Ospedaliero Universitaria di Cagliari, 09042 - Monserrato/IT
  • 10 Oncology, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 11 Uoc Di Oncologia Medica, Policlinico Universitario A. Gemelli, 00168 - Rome/IT
  • 12 Oncology Department, ospedale santo spirito, 00198 - rome/IT
  • 13 Oncology Department, Ospedale di Legnago, 37045 - Legnago/IT
  • 14 Medical Oncology, Azienda Ospedaliero Universitaria di Cagliari, 8040 - Cagliari/IT
  • 15 Asuits, Centro Sociale Oncologico (CSO), 34129 - Trieste/IT
  • 16 Onco-ematologia, Ospedale Belcolle, 01100 - Viterbo/IT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3034


In HER2+ breast cancer (BC) patients (pts) the pathological complete response (pCR) is associated with improved survival. With regimens based on the combination of trastuzumab (T), pertuzumab (P) and chemotherapy, pCR rates are slightly over 48%. We conducted a retrospective analysis on HER2+ BC pts to describe the outcomes of neoadjuvant combination of P+T and chemotherapy in the real-life setting.


Our cohort included 64 pts treated between Sept 2015 and Mar 2018 in 15 Italian Cancer Centers. Treatment outcomes were analyzed in terms of pCR (defined as ypT0/Tis, ypN0i-) and toxicities, recorded according to National Cancer Institute Common Toxicity Criteria. Statistical analysis was performed with T di Student test and χ2 test.


Overall, in the 55 evaluable pts median age was 50 (range 28-77) and 29 pts (53%) were pre-menopausal. 24 pts (45%) were ER-/PgR-, 12 (21%) ER+/PgR-, 16 (29%) ER+/PgR+, median ki67 was 40. 9% of pts were cT1, 73% cT2, 13% cT3 and 5% cT4; 42 pts (76%) were cN+. All pts received 4 cycles of T (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) and P (loading dose 840 mg, followed by 420 mg every 3 weeks). In 42 pts T+P were administered with docetaxel (75 mg/mq every 3 weeks), in 8 pts with paclitaxel (80 mg/mq) and 5 pts received docetaxel and carboplatin (AUC5). In 13 pts also 3 cycles of anthracyclines, according to the FEC scheme, were administered. A pCR was achieved in 29 pts (53%). No significant associations were found between pCR and baseline characteristics or treatments schedule. Seven out of 55 (13%) pts reported G3-G4 toxicities (5 pts neutropenia G3-G4, 1 pt vomiting G3, 1 pt diarrhoea G3, 1 pt anemia G3). Three out of 4 pts treated with docetaxel, carboplatin and P+T reported G3/G4 toxicities. A significant association was found between chemotherapy schedule and toxicities (p = 0.004).


The association of P+T+chemotherapy improved pCR rate in HER2+ BC pts treated in the real-life setting. Our results showed that the selection of chemotherapy that will be associated with the dual blockade of HER2 is of paramount importance in order to avoid severe toxicities and increase the compliance with treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Department of Oncology, Belcolle Hospital.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.